DE-LYCRA
27.7.2021 11:02:09 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative solutions for the textile, apparel, and personal care industries, today introduced a breakthrough LYCRA® FitSense™ technology innovation that reduces or eliminates the need for bra foam. This patent-pending bra cup application can be used in intimate apparel such as traditional wired, non-wired or unlined bras (including bralettes and sport bras), plus activewear and swimwear.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005390/en/
LYCRA® FitSense™ technology is a water-based, solvent-free dispersion that is comprised of the same molecule as LYCRA® fiber. The dispersion is screen-printed directly onto the bra fabric, increasing the power of the fabric in precise areas. The power increase in the bra cup effectively reduces nipple protrusion while providing symmetrical support, shaping and lift for the bustline—reducing or eliminating the need for sewn-in panels or insertable pads.
Zones of support can be applied to the bottom and sides of the bra cup for shaping, as well as the wing for maximum comfort and smoothing. LYCRA® FitSense™ technology also can be applied between fabric layers in the bra cup to mask nipple protrusion while retaining the original fabric aesthetics.
“With LYCRA® FitSense™ technology, the print does the work of the pad and enables brands to build a better bra for all sizes, styles and silhouettes—a true breakthrough development,” said Melissa Stewart, global technology director-R&D materials innovations. “With this new innovation, women have more choices in bras that provide functionality, style and comfort.”
Bras can be rigid, bulky, and hot, with multiple components and structures creating an uncomfortable, restrictive wearing experience. LYCRA® FitSense™ technology can be used to design functional bras that are lighter, thinner, and more breathable, without sacrificing modesty, all-day comfort, durability, support or shaping. And unlike polyurethane foam—which discolors and can move around or even get lost in the wash—LYCRA® FitSense™ technology is built into the garment and is highly durable to machine washing and regular wear. Further, in swimwear applications, the technology provides chlorine resistance and fast drying benefits versus foams and dual fabric layers.
LYCRA® FitSense™ technology offers intimate apparel makers versatility to create intentional design aesthetics by incorporating delicate patterns and artistic details that align with their brand identities. “Designs and colors can be easily customized to deliver on-trend fashion cues—from feminine, lacelike designs to sporty geometric shapes—that satisfy all tastes,” said Stewart. “With LYCRA® FitSense™ technology, a designer’s imagination is the only creative limitation.”
LYCRA® FitSense™ technology, which achieved the ECO PASSPORT by OEKO-TEX® sustainability certification, is applied using standard screen-printing processes, eliminating the need for specialty equipment or major supply chain upgrades. The LYCRA Company provides technical guidance to enable brands, retailers, and garment makers to easily access this innovation.
For more information, download our white paper on the LYCRA FitSense™ technology and screen-printed bra cup application.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® FitSense™ is a trademark of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom